Study No | Age at transplant/IPSS score | Original MDS Diagnosis | Pre-transplant MDS Diagnosis | Immediate pre-transplant Marrow Biopsy (following cytoreductive therapy) | Post-transplant Assessment 1 | Post-transplant Assessment 2 | Post-transplant Assessment 3 | Post-transplant Assessment 4 | Follow-up | Cytogenetics Comparison |
---|---|---|---|---|---|---|---|---|---|---|
Diagnosis/CG | Diagnosis/CG | Diagnosis/CG | Morphologic Conclusion/Engraftmenta/CG | Morphologic Conclusion/Engraftmenta/CG | Morphologic Conclusion/Engraftmenta/CG | Morphologic Conclusion/Engraftmenta/CG | Status/Relapse Treatment | |||
7 | 61/INT-1 | RARS /46,XX,del(12)(p11.2p13) [7]/46,XX [13] | RARS/46,XX,del(12)(p11.2p13) [3]/46,XX [17] | No intervening marrows pre-transplant | Indeterminate /6 /Neg by FISH | MDS with dyerythropoiesis and numerous ring sideroblasts, no increase in blasts c /88 /46,XX[49]//46,XY[1] | Deceased of invasive aspergillus lung infection with persistent MDS/ reduction in immunosuppression then DLI for subsequent RAEB-1 | Some similarities between clones | ||
Daysb | −699 | −15 | 23 | 100 | 237/137 (post-relapse) | |||||
27 | 69/Unknown | RCMD-RS | RCMD-RS/45,XY,-7,del(20q)(q11.2q13.1) [3] | No intervening marrows pre-transplant | Indeterminate /30.6 / monosomy 7 by FISH (8% interphase cells) | Negative /0 /monosomy 7 by FISH (2.75%, slightly above normal control range) | Negative /0 /not performed | MDS with dysmegakaryopoiesis, numerous ring sideroblasts, no increase in blasts /12.6 /45,XY,-7,del(20q)(q11.2q13.3)[3]/46,XY[12] | Unknown/ Unknown | Same abnormal clone |
Days | −111 | −31 | 22 | 60 | 98 | 155 | ||||
32 | 62/INT-1 | RAEB-1 | RAEB-2/clone with trisomy 8 | Hypercellular marrow withno increase in blasts; 3.25% by FISH with extra chromosome 8 | Indeterminate /6.1 /Neg by FISH | Indeterminate /11.8 /Neg by FISH and karyotype | AML /41.8 /46,XX,t(2;3)(q23;q26–27)[4]/46,XX[14] | Unknown/ Unknown | Different abnormal clone | |
Days | −376 | −141 | −29 | 33 | 63 | 98 | ||||
34 | 49/HIGH | RAEB-1 /complex karyotype including deletion of 5q | Same specimen as original MDS diagnosis | Normocellular marrow with no increase in blasts/cytogenetics not performed | Negative /57.4 /Neg by FISH | Negative /29.6 /loss of chromosome 5 by FISH (6.75% interphase cells) and complex karyotype | MDS with dysgranulopoiesis, borderline increased marrow blasts, and rare circulating blasts / 20.3/FISH: 19.5% had a signal pattern indicative of loss of both 5p15.2 and q31 | Unknown/ Unknown | Some similarities between clones | |
Days | −200 | −25 | 21 | 36 | 65 | |||||
58 | 67/LOW | MDS with isolated del(5q) /46,XY,del(5)(q13q33) [18]/46,XY [2] | RAEB-2/46,XY,del(5)(q22q33) [18]/46,XY [2] | No intervening marrows pre-transplant | Indeterminate /0 /Neg by FISH | Indeterminate /3 /Neg by FISH | RAEB-1 /38 /46,XY,del(5)(q22q35)[11*]/46,XY[7]/46,XX[2] | Unknown/ Unknown | Same abnormal clone | |
Days | −458 | −25 | 21 | 98 | 137 | |||||
63 | 68/INT-2 | RCMD-RS /45~46,XY,add(4)(q31),del(5)(q15q33),del(7)(q22q34),+8,del(11)(q14q23),add(12)(p11.2),dic(14;15)P(11.2;p11.2),add(17)(p11.2),-18,01mar[cp18]/46,XY [2] | RAEB-2/44–46,XY,-3,del(4)(q31q35),del(5)(q15q33),del(7)(q22q36),+8,del(11)(q21q23),add(12)(p11.2),dic(14;15)(p11.2;p11.2),-17,-18,+2mar[cp5] | Normocellular marrow with no increase in blasts/ Negative by FISH | Negative /2.9 /Neg by FISH | RAEB-2 /91.8 /FISH: 83% had a signal pattern consistent with deletion of the long arm of one chromosome 5 | Unknown/ azacitidine | Some similarities between clones | ||
Days | −298 | −126 | −15 | 21 | 90 | 129/39 (post-relapse) | ||||
78 | 69/LOW | RARS-T /46,XY,dup(1)(q21q43) [14]/46,XY,der(15)t(1;15)(q12;p11.2) [3]/46,XY [3] | Same specimen as original MDS diagnosis d | No intervening marrows pre-transplant | Indeterminate/0 /Neg by FISH | Negative/7 /Neg by FISH | Abnormal with 5% ring sideroblasts /14 /46,XY,dup(1)(q21q43)[2]/46,XY,der(15)t(1;15)(q12;p11.2)[1*]/46,XY[17] | Deceased with steroid refractory late acute GVHD/No intervention | Same abnormal clone | |
Days | −21 | 23 | 100 | 174 | 232/58 (post-relapse) | |||||
79 | 70/INT-2 | RAEB-1 /43–44, XX, −5, −7, −19, −22, +12mar [3]/4245, sl, −18, +14[11]/46,XX [6] | Same specimen as original MDS diagnosis | Persistent MDS with 3% marrow blasts/44,XX,-5,-7,-18,-19,-22,+3mar [2]/46,XX [19] | Negative/ not performed /Neg by FISH | Suspicious for myeloid neoplasm with slight trilineage dyspoiesis and 4% to 5% blasts /23 /44,XX,-5,-7,-19,-22,+mar1,+mar2[3]/43,idem,-18[2]//46,XY[15] | Alive currently undergoing treatment for relapse (as AML) that occurred 2 years after DLI/ immunosuppression withdrawal | Same abnormal clone | ||
Days | −70 | −28 | 20 | 90 | 625/535 (post-relapse) | |||||
81 | 71/INT-1 | RAEB-1 | RAEB-1/Normal karyotype | No evidence of residual disease/cytogenetics not performed | Negativee /38 /normal karyotype | RAEB-1 / 26/46,XX[19] | Deceased with persistent disease/withdrawal of immunosuppression then ALT-803 trial | No clonal abnormality pre-transplant disease and relapse | ||
Days | −735 | −165 | −38 | 21 | 98 | 465/367 (post-relapse) | ||||
82f | 34/INT-1 | RCMD /46,XY,add(6)(?p21.2) [18]/46,XY [2] | RAEB-1/46,XY,add(6)(p21.1) [20] | No intervening marrows pre-transplant | Indeterminate/0 /normal karyotype | Indeterminate /0 /normal karyotype | Indeterminate /1 /not performed | AML /66 /46,XY,add(6)(p21.1)[4]/46,idem,t(9;14)(q34;q24)[14]/46,X,t(Y;1)(p11.3;q21),del(4)(q11), der(13)t(4;13)(q11;p13),add(6)[2] | Deceased with persistent disease/ 7 + 3 induction, ALT-803, GCLACchemotherapy, azacitidine, DLI | Clonal evolution |
Days | −230 | −35 | 21 | 62 | 99 | 139 | 374/235 (post-relapse) |